|Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.|
|PMID: 22537439 Owner: NLM Status: MEDLINE|
|With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity and mortality among patients with both infections (coinfection). In addition to the high prevalence of chronic HCV, particularly among HIV-infected injection drug users, the rate of incident HIV infections is increasing among HIV-infected men who have sex with men, leading to recommendations for education and screening for HCV in this population. Liver disease is the second leading and, in some cases, a preventable cause of death among coinfected patients. Those at risk for liver disease progression are usually treated with a combination of interferon (IFN) and ribavirin (RBV), which is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinfected patients with HCV genotype 1 and those of African descent. Direct-acting antivirals might overcome factors such as immunodeficiency that can reduce the efficacy of IFN. However, for now it remains challenging to treat coinfected patients due to interactions among drugs, additive drug toxicities, and the continued need for combination therapies that include pegylated IFN. Recently developed HCV protease inhibitors such as telaprevir and boceprevir, given in combination with pegylated IFN and RBV, could increase the rate of SVR with manageable toxicity and drug interactions. We review the latest developments and obstacles to treating coinfected patients.|
|Susanna Naggie; Mark S Sulkowski|
Related Documents :
|22824629 - Chronic immune activation and decreased cd4 cell counts associated with hepatitis c inf...
22375699 - Changes in hiv risk behavior and seroincidence among clients presenting for repeat hiv ...
22550529 - Prevalence of hepatitis d virus infection among hepatitis b virus infected patients in ...
22895429 - Recommendations for the identification of chronic hepatitis c virus infection among per...
22737229 - Genome-wide association study confirming association of hla-dp with protection against ...
7567149 - Clinical utility of the polymerase chain reaction to diagnose mycoplasma pneumoniae inf...
3285669 - False-positive results of screening for antibodies to human immunodeficiency virus in c...
3368939 - Follow-up testing and notification of anti-hiv western blot atypical (indeterminant) do...
19803679 - Long-term combination antiretroviral therapy is associated with the risk of coronary pl...
|Type: Journal Article; Research Support, N.I.H., Extramural; Review|
|Title: Gastroenterology Volume: 142 ISSN: 1528-0012 ISO Abbreviation: Gastroenterology Publication Date: 2012 May|
|Created Date: 2012-04-27 Completed Date: 2012-06-18 Revised Date: 2014-09-13|
Medline Journal Info:
|Nlm Unique ID: 0374630 Medline TA: Gastroenterology Country: United States|
|Languages: eng Pagination: 1324-1334.e3 Citation Subset: AIM; IM|
|Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.|
|APA/MLA Format Download EndNote Download BibTex|
analogs & derivatives,
Anti-HIV Agents / therapeutic use
Antiviral Agents / adverse effects, pharmacokinetics, pharmacology*, therapeutic use*
Deoxycytidine / analogs & derivatives, therapeutic use
Dideoxynucleosides / therapeutic use
Drug Administration Schedule
Drug Therapy, Combination
HIV Infections / drug therapy*, epidemiology, etiology
Hepatitis C, Chronic / drug therapy*, epidemiology, etiology
Interferon-alpha / therapeutic use
Lamivudine / therapeutic use
Liver Cirrhosis / virology
Liver Diseases / prevention & control, virology*
Oligopeptides / therapeutic use
Organophosphonates / therapeutic use
Polyethylene Glycols / therapeutic use
Proline / analogs & derivatives, therapeutic use
Pyrrolidinones / therapeutic use
Recombinant Proteins / therapeutic use
Ribavirin / therapeutic use
Serine Proteinase Inhibitors / therapeutic use
Substance Abuse, Intravenous / complications
|DA-16065/DA/NIDA NIH HHS; K23 AI096913/AI/NIAID NIH HHS; K23-AI096913-02/AI/NIAID NIH HHS; K24 DA034621/DA/NIDA NIH HHS; R01 DA016065/DA/NIDA NIH HHS; R01 DA016065-10/DA/NIDA NIH HHS|
|0/Anti-HIV Agents; 0/Antiviral Agents; 0/Dideoxynucleosides; 0/Interferon-alpha; 0/N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; 0/Oligopeptides; 0/Organophosphonates; 0/Polyethylene Glycols; 0/Pyrrolidinones; 0/Recombinant Proteins; 0/Serine Proteinase Inhibitors; 0/emtricitabine; 0/peginterferon alfa-2a; 0/telaprevir; 0W860991D6/Deoxycytidine; 107021-12-5/tenofovir; 22VKV8053U/raltegravir; 2T8Q726O95/Lamivudine; 49717AWG6K/Ribavirin; 9DLQ4CIU6V/Proline; JAC85A2161/Adenine; WR2TIP26VS/abacavir|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Next Document: Anti-hepatitis C virus drugs in development.